| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANA.410300409 |
| P8608 | Fatcat ID | release_cs4vjd3qjzfrxmxujt74hs2coa |
| P698 | PubMed publication ID | 1665052 |
| P2093 | author name string | Tanaka M | |
| Mizuno Y | |||
| Ozawa T | |||
| Hattori N | |||
| P2860 | cites work | Immunocytochemical demonstration of cytochrome c oxidase with an immunoperoxidase method: a specific stain for mitochondria in formalin-fixed and paraffin-embedded human tissues | Q34043566 |
| P433 | issue | 4 | |
| P921 | main subject | mitochondrion | Q39572 |
| Parkinson's disease | Q11085 | ||
| immunohistochemistry | Q899285 | ||
| P304 | page(s) | 563-571 | |
| P577 | publication date | 1991-10-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease | |
| P478 | volume | 30 |
| Q37357084 | (ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson's disease |
| Q43089180 | A diet for dopaminergic neurons? |
| Q30411177 | A heme oxygenase-1 transducer model of degenerative and developmental brain disorders |
| Q37963718 | Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders |
| Q54965150 | Advances in genetic models of Parkinson's disease |
| Q40460527 | Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system |
| Q48704507 | An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease |
| Q33812214 | Analysis of the mitochondrial proteome in multiple sclerosis cortex |
| Q36929398 | Behavioral and metabolic characterization of heterozygous and homozygous POLG mutator mice |
| Q64870168 | Biochemical Profiling of the Brain and Blood Metabolome in a Mouse Model of Prodromal Parkinson's Disease Reveals Distinct Metabolic Profiles |
| Q38127703 | Can parkin be a target for future treatment of Parkinson's disease? |
| Q51193041 | Carnosic Acid Suppresses the H2O2-Induced Mitochondria-Related Bioenergetics Disturbances and Redox Impairment in SH-SY5Y Cells: Role for Nrf2. |
| Q37168743 | Cognitive Impairment Associated with Parkinson's Disease: Role of Mitochondria |
| Q48865955 | Cytochrome c oxidase defects of the human substantia nigra in normal aging |
| Q43256162 | D-beta-hydroxybutyrate prevents MPP+-induced neurotoxicity in PC12 cells |
| Q71616123 | Decreased cytochrome c oxidase activity but unchanged superoxide dismutase and glutathione peroxidase activities in the spinal cords of patients with amyotrophic lateral sclerosis |
| Q35709827 | Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 1993-2003: where are we 10 years on? |
| Q33186270 | Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson's disease |
| Q64251001 | Dietary Macronutrient Management to Treat Mitochondrial Dysfunction in Parkinson's Disease |
| Q48576376 | Dimethoxyphenylethylamine and tetrahydropapaverine are toxic to the nigrostriatal system |
| Q48317832 | Do defecs in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? |
| Q42132131 | Do somatic mitochondrial DNA mutations contribute to Parkinson's disease? |
| Q48494914 | Effects of partial inhibition of respiratory complex I on H2O 2 production by isolated brain mitochondria in different respiratory states |
| Q26795417 | Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics |
| Q33944937 | Energetics in the pathogenesis of neurodegenerative diseases |
| Q100945760 | Functional validation of a human GLUD2 variant in a murine model of Parkinson's disease |
| Q24312172 | Genotype in the 24-kDa subunit gene (NDUFV2) of mitochondrial complex I and susceptibility to Parkinson disease |
| Q38918493 | Imaging and spectroscopic approaches to probe brain energy metabolism dysregulation in neurodegenerative diseases |
| Q37671552 | Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease |
| Q54976406 | LRRK2 and mitochondria: Recent advances and current views. |
| Q34133422 | Leucine-rich repeat kinase 2: a new player with a familiar theme for Parkinson's disease pathogenesis |
| Q37302025 | Light microscopic methods to visualize mitochondria on tissue sections |
| Q24680250 | Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27 |
| Q46691979 | Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease |
| Q38648684 | Membrane lipids as therapeutic targets for Parkinson's disease: a possible link between Lewy pathology and membrane lipids |
| Q43708031 | Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: an in situ hybridization study |
| Q64117267 | Metabolomics-based identification of metabolic alterations in PARK2 |
| Q64982582 | Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson's Disease Patients. |
| Q35852144 | Mitochondrial DNA Depletion in Respiratory Chain-Deficient Parkinson Disease Neurons. |
| Q33364885 | Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease |
| Q35412397 | Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? |
| Q47820662 | Mitochondrial complex I, II/III, and IV activities in familial and sporadic Parkinson's disease |
| Q38811534 | Mitochondrial control of cell bioenergetics in Parkinson's disease. |
| Q35891905 | Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment |
| Q27014051 | Mitochondrial dysfunction and oxidative stress in Parkinson's disease |
| Q30444758 | Mitochondrial dysfunction and oxidative stress in Parkinson's disease. |
| Q41547386 | Mitochondrial dysfunction in neurodegeneration |
| Q33540916 | Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia |
| Q29615627 | Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants |
| Q37699222 | Mitochondrial therapies for Parkinson's disease |
| Q48151350 | Mitochondrial-Associated Membranes in Parkinson's Disease |
| Q33951094 | Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease |
| Q48598969 | Native DIGE proteomic analysis of mitochondria from substantia nigra and striatum during neuronal degeneration and its compensation in an animal model of early Parkinson's disease |
| Q47572328 | Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage |
| Q35886715 | Neuronal pathology in Parkinson's disease |
| Q48726366 | Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture |
| Q40653060 | Neurotrophins and their receptors in nerve injury and repair. |
| Q35243818 | New morphological approaches to the study of mitochondrial encephalomyopathies |
| Q36796199 | Optical imaging techniques (histochemical, immunohistochemical, and in situ hybridization staining methods) to visualize mitochondria |
| Q48864554 | Optical imaging techniques (histochemical, immunohistochemical, and in situ hybridization staining methods) to visualize mitochondria |
| Q84152956 | Oral administration of coenzyme Q₁₀ reduces MPTP-induced loss of dopaminergic nerve terminals in the striatum in mice |
| Q26798897 | Oxidative stress and Parkinson's disease |
| Q35750160 | Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model |
| Q44640820 | Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration |
| Q37143657 | Progress in the pathogenesis and genetics of Parkinson's disease |
| Q44691515 | Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions |
| Q36449306 | Recessive Parkinson's disease |
| Q34380871 | Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein |
| Q40437315 | Role of mitochondria in the etiology and pathogenesis of Parkinson's disease |
| Q38790569 | Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders |
| Q48379932 | Sodium pump evokes high density pump currents in rat midbrain dopamine neurons |
| Q43375837 | Testosterone Upregulates the Expression of Mitochondrial ND1 and ND4 and Alleviates the Oxidative Damage to the Nigrostriatal Dopaminergic System in Orchiectomized Rats. |
| Q38374332 | The Parkinson Disease Mitochondrial Hypothesis: Where Are We at? |
| Q35799141 | Toxin models of mitochondrial dysfunction in Parkinson's disease. |
| Q30373545 | Two dimensional blue native/SDS-PAGE to identify mitochondrial complex I subunits modified by 4-hydroxynonenal (HNE). |
| Q46333422 | Variable effects of chronic subcutaneous administration of rotenone on striatal histology |
| Q46579323 | iPS cells in the study of PD molecular pathogenesis |
Search more.